Avalo Therapeutics AVTX Income Statement
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| $14.05M+54.0% | $13.27M+62.1% | $13.62M+42.8% | $14.07M+206% | $9.12M+331% | ||
| $6.85M+23.6% | $6.53M+24.9% | $5.58M+30.1% | $5.24M+15.8% | $5.55M+73.7% | ||
| $20.9M+42.5% | $19.8M+46.6% | $19.2M+46.4% | $19.32M+102% | $14.67M-55.2% | ||
| -$20.9M-42.5% | -$19.74M-48.3% | -$19.2M-49.3% | -$19.32M-102% | -$14.67M+55.2% | ||
| $803K-30.1% | $984K-18.7% | $1.12M+15.9% | $1.1M+6.1% | $1.15M+1,048% | ||
| $1.28M-16.0% | —— | -$11.42M-132% | -$1.43M-101% | $1.53M+102% | ||
| -$19.62M-49.3% | -$13.59M+61.4% | -$30.61M-233% | -$20.75M-121% | -$13.14M+89.2% | ||
| $12K+50.0% | $130K+14.0% | $11K+179% | $16K+129% | $8K+14.3% | ||
| -$19.63M-49.3% | -$13.72M+61.2% | -$30.63M-233% | -$20.77M-121% | -$13.15M+89.2% | ||
| -$0.98+21.6% | -$0.37— | -$2.19+22.6% | -$1.92+86.4% | -$1.25+99.1% | ||
| -$20.88M-43.7% | -$19.73M-49.0% | -$19.14M-49.2% | -$19.18M-101% | -$14.53M+55.6% | ||
| -$20.9M-42.5% | -$19.74M-48.3% | -$19.2M-49.3% | -$19.32M-102% | -$14.67M+55.2% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Is Avalo Therapeutics profitable?
- Avalo Therapeutics is not currently profitable: it reported a net loss of $84.7M over the trailing twelve months, a -7965.8% net margin.
- What are Avalo Therapeutics's profit margins?
- Gross margin is 182.0% and operating margin is -15536.1%, with a -7965.8% net margin.
- What is Avalo Therapeutics's earnings per share?
- Avalo Therapeutics's diluted EPS over the trailing twelve months is $-5.46.
- Where does Avalo Therapeutics's income statement data come from?
- Every line is extracted from Avalo Therapeutics's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.